Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan Preoperative Preparation in Pheochromocytoma/Paraganglioma
ChiCTR2600120686Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belzutifan in pheochromocytoma and Paraganglioma (PGL), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Plasma metanephrines. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on ChiCTR2600120686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120686.